Atara Biotherapeutics, Inc - ATRA STOCK NEWS

Atara Biotherapeutics has announced that its Independent Data and Safety Monitoring Committee (IDSMC) recommended continuing the ATA188 Phase 2 study without adjusting the sample size. The IDSMC did not identify any safety concerns during its evaluation, focusing on the expanded disability status scale (EDSS) and biomarker data. The company achieved its target enrollment of 80 patients and anticipates sharing finalized results in October 2023.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced it will release results from the ATA188 Phase 2 EMBOLD Study Interim Analysis on July 12, 2022, after market close. The study focuses on tackling EBV antigens for potential multiple sclerosis therapy. Following the press release, a live conference call and webcast will occur at 5:00 p.m. EDT. Atara is recognized for its advancements in T-cell immunotherapy, with ongoing clinical programs targeting serious diseases, including solid tumors and autoimmune disorders.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the grant of 31,515 restricted stock units and stock options for 15,227 shares to newly hired employees as part of their 2018 Inducement Plan. The awards were approved by Atara's Compensation Committee and are designed to attract talent under Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with a 25% initial vest on the first anniversary. The stock options have a ten-year term and an exercise price of $8.30 per share, reflecting the stock's closing price on the grant date of July 1, 2022.

Atara Biotherapeutics announced promising results from its Expanded Access Program (EAP) for tabelecleucel (tab-cel) in treating EBV+ PTLD, reporting a 60% overall response rate in patients. Data from 16 treated patients revealed 6 complete and 3 partial responses, with most responses occurring after the first treatment cycle. The company has completed all pre-approval inspections necessary for its EU Marketing Authorization Application, anticipating approval by Q4 2022. These milestones highlight Atara's advancement in T-cell immunotherapy targeting serious diseases.

Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 126,928 restricted stock units and stock options for newly hired employees, totaling 186,378 shares. These awards were approved by the Compensation Committee and are part of Atara's 2018 Inducement Plan, effective June 1, 2022. The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price of $4.83 per share. This action complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent while supporting the company’s growth in T-cell immunotherapy.

Atara Biotherapeutics (NASDAQ: ATRA) announced that Bayer intends to terminate their exclusive worldwide licensing agreement for next-gen mesothelin-directed CAR T-cell therapies, including ATA3271 and ATA2271, aimed at high mesothelin-expressing tumors. This follows Bayer's strategic review prioritizing its pipeline. Atara will regain rights to continue clinical development and commercialization of the therapies and will proceed with ongoing studies, including a Phase 1 trial for ATA2271, even as patient enrollment is paused temporarily. The company will postpone the IND filing for ATA3271 beyond Q4 2022 while maintaining cash runway guidance into Q4 2023.

Atara Biotherapeutics (NASDAQ: ATRA) announced the approval of 115,059 restricted stock units and 118,745 stock options for newly hired employees. This grant took place on May 2, 2022, under their 2018 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price of $6.94 per share. This strategic move aims to attract talent as Atara develops therapies for serious diseases utilizing its T-cell immunotherapy platform.

Atara Biotherapeutics (ATRA) reported strong progress in Q1 2022, with an upcoming interim analysis of ATA188 for progressive multiple sclerosis scheduled for June. Financial highlights include a cash balance of $301.8 million as of March 31, 2022, sufficient to fund operations into Q4 2023, bolstered by a $100 million sale of a cell therapy manufacturing facility. Notably, tab-cel's review by the EMA is on track for EC approval in Q4 2022, while Atara advances partnerships and clinical trials for its innovative therapies.

Atara Biotherapeutics (NASDAQ: ATRA) has granted inducement awards to its new Executive Vice President and Chief Technical Officer, Charlene Banard. The awards include 155,350 restricted stock units, time-based stock options for 292,023 shares, and performance-based options for 33,184 shares, all effective as of April 25, 2022. The vesting of these options is contingent on Banard’s continued employment and achieving certain performance goals. The exercise price for the stock options is set at $7.29 per share, equal to the stock's closing price on the grant date.